R & D

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer

 This material is intended to notify the press release issued on March 4 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click for the original press release.